Dominantly Inherited Alzheimer Network (DIAN)

What is the purpose of this study?

The Dominantly Inherited Alzheimer Network (DIAN) is a major study of families with a gene mutation that causes Alzheimer’s disease at a much younger age, sometimes as young as in their 30s or 40s. By tracking brain changes before symptoms appear and comparing people with and without the mutation, researchers hope to uncover the earliest signs of the disease. These insights could lead to better ways to prevent, delay, or treat Alzheimer’s for everyone. Visit the DIAN website for more information about the study and to learn if you are eligible to participate.

Who is a qualifying participant?

• Adults aged 18 or older.
• One or both parents have/had a genetic mutation known to cause autosomal dominant Alzheimer's disease OR experienced symptoms consistent with Alzheimer’s disease before the age of 60.
• Participants must be cognitively normal or have only very mild to mild cognitive impairment.
• Each participant must identify at least one (ideally two) individual(s) who are not full siblings to serve as collateral sources (study partners) to provide information on their memory and daily functioning.
• Fluent in English or Spanish.

What are we asking of you in this study?

We ask for an annual visit. Participation is ongoing as long as you wish to participate or until the study closes. During your visits, we will ask for

• Medical History: More detailed questions about your medical history, medications, family history, social history, and health habits.
• Vital Signs: Measures of blood pressure, temperature, pulse, height, weight, waist and hip circumference.
• Bloodwork: Blood is drawn to collect important health information and risk factors. (This study does not provide lab results for this bloodwork)
• Cognitive Testing: Written tests and questions will be administered by an examiner to evaluate memory and thinking.
• Neurological Evaluation: A doctor will conduct a neurological/physical exam.
• Imaging: MRI scans to measure brain structure changes over time; PET scans to look for amyloid and tau deposits (hallmarks of Alzheimer's disease).
• Cerebrospinal Fluid Collection: A lumbar puncture (LP) to measure Alzheimer’s-related proteins (amyloid and tau). (For more information, click here)
• Optional Tests: DNA analysis to determine genetic status (not required).